Genzyme's search for a vector

Genzyme Corp.'s decision on Friday to exercise its option to exclusively license Vical Inc.'s cytofectin non-viral vector technology for cystic fibrosis served as a reminder that gene therapy remains at an early stage of development, despite the plethora of ongoing clinical trials.

In addition to VICL's cationic lipid vectors, GENZ is pursuing adenoviral and other viral vector approaches to CF.